Old GLP-1 Generics Could Drive Down Costs of New Versions
Recently, two of the oldest GLP-1 drugs have become available in generic form. This development could potentially lead to Medicare negotiating lower prices for brand-name versions of drugs like Ozempic, which contains semaglutide. This comes at a crucial time as Medicare is considering covering these medications for weight loss.
With the introduction of generic versions of these older GLP-1 drugs, there is a possibility of significant cost savings for patients and healthcare systems. The landscape of GLP-1 medications is evolving rapidly, and understanding how these generics may impact the prices of current blockbuster drugs is essential.
To delve deeper into the intricacies of this issue and its potential implications for patients and healthcare providers, access the full story on STAT+.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
